A Phase 2 interventional study of Active PRA-216 and Placebo in Atopic Dermatitis (AD), sponsored by Prana Therapies Inc. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Prana Therapies Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Dermatitis, Atopic with a site in Australia — 12 open to participants now, 27 under way, 7 of them phase 3. Dermatitis, Atopic · Australia.
Among the 110 studies in Dermatitis, Atopic with a site in Australia, this one is the 95th largest by planned enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2026, is one of 40 in phase 2, reaches primary completion later than 14 of the 26 other live ones, and was the 109th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →12 of the 110 studies in Dermatitis, Atopic with a site in Australia are open now. Recruiting first, the newest first:
Bionyra Pharma · Sites in Australia
Ages 18–55 · Healthy volunteers
Seismic Therapeutic AU Pty Ltd · Sites in Australia
Ages 18–75
Zai Lab (Shanghai) Co., Ltd. · Sites in Australia, China, New Zealand
Ages 18–65 · Healthy volunteers
Inmagene LLC · Sites in Australia, United States, Canada and 1 more country
Ages 18–74
TRex Bio, Inc. · Sites in Australia, New Zealand
Ages 18–70 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 44 · Phase 3 39 · Phase 4 5
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 39 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 226 across the 105 interventional studies, 914 across the 4 observational. Of the 81 that completed or were terminated, 56 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 110 have an industry lead sponsor. The 10 most frequent:
Prana Therapies Inc is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Prana Therapies Inc has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
8 of the studies in Dermatitis, Atopic with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06808477Bambusa TherapeuticsA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) | 2027-02-28 |
| NCT07549750Helixon Biotechnology (Suzhou) Co., LtdA Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants | 2027-03-18 |
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
| NCT07217015Kymera Therapeutics, Inc.A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 110 studies in Dermatitis, Atopic with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy response of PRA-216 in patients with moderate to severe Atopic Dermatitis (AD). Eligible participants will be those with AD who are inadequately controlled by topical corticosteroids (TCS) or had adverse reaction or contraindication to the medication.
This study will enroll approximately 39 participants at multiple study sites who will be randomized 2:1 to receive either PRA-216 or placebo subcutaneous injections four times throughout the study period.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate to severe AD will be randomized to receive PRA-216
Drug: Active PRA-216
Participants with moderate to severe AD will be randomized to receive placebo
Drug: Placebo
biologic
matching placebo for PRA-216
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of PRA-216 in patients with moderate to severe atopic dermatitis (AD)
Time frame: Up to 28 weeks
Clinical efficacy of PRA-216 compared to placebo in participants with moderate to severe AD
Mean percent change from baseline in Eczema Area and Severity Index (EASI). EASI is a score that will grade atopic dermatitis, with a higher number indicating more severe disease. A score of 0 indicates clear skin, and a score of 72 is severe disease.
Time frame: Up to 24 weeks
Clinical efficacy of PRA-216 compared to placebo in participants with moderate to severe AD: EASI-75
Percentage of patients achieving EASI-75. EASI-75 indicates a 75% improvement in severity and spread of skin lesions compared to baseline.
Time frame: Up to 24 weeks
Clinical efficacy of PRA-216 compared to placebo in participants with moderate to severe AD: EASI-90
Percentage of patients achieving EASI-90. EASI-90 indicates a 90% improvement in severity and spread of skin lesions compared to baseline.
Time frame: Up to 24 weeks
Pharmacokinetics of PRA-216: Tmax in patients with AD
Time to maximum concentration of drug in plasma
Time frame: Up to 28 weeks
Pharmacokinetics of PRA-216: AUC in patients with AD
Area under the curve
Time frame: Up to 28 weeks
Pharmacokinetics of PRA-216: Cmax in patients with AD
Maximum concentration of PRA-216 in plasma
Time frame: Up to 28 weeks
Immunogenicity of PRA-216: ADA in patients with AD
Incidence of anti-drug antibody following drug administration
Time frame: Up to 24 weeks
Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 12 months is close to that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2027 → Sep 2027 and completion Oct 2027 → May 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prana Therapies Inc